Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Oct;47(10):3040-5.
doi: 10.1128/AAC.47.10.3040-3045.2003.

Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods

Catherine Liu  1 , Henry F Chambers
Affiliations
Review

Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods

Catherine Liu et al. Antimicrob Agents Chemother. 2003 Oct.
No abstract available

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Population analysis of VRSA, VISA, hVISA, and VSSA. The population analysis shows how many cells in a fixed number of cells (usually about 107 CFU) of each strain are resistant to various concentrations of vancomycin. VRSA is a highly resistant and homogeneously resistant strain with 100% of the population growing at each of the vancomycin concentrations tested. VISA is intermediately resistant with 100% of the population growing at 4 μg of vancomycin per ml and also with significant subpopulations growing at 8 μg/ml. hVISA demonstrates heterogeneous resistance, having subpopulations of cells with various levels of resistance to vancomycin and including small populations of vancomycin-intermediate resistant cells with growth at 8 μg of vancomycin per ml.
See this image and copyright information in PMC

References

    1. Ariza, J., M. Pujol, J. Cabo, C. Pena, N. Fernandez, J. Linares, J. Avats, and F. Gudiol. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588. - PubMed
    1. Bierbaum, G., K. Fuchs, W. Lenz, C. Szekat, and H. G. Sahl. 1999. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur. J. Clin. Microbiol. Infect. Dis. 18:691-696. - PubMed
    1. Bobin-Dubreux, S., M.-E. Reverdy, C. Nervi, M. Rougier, A. Bolmström, F. Vandenesch, and J. Etienne. 2001. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative. Antimicrob. Agents Chemother. 45:349-352. - PMC - PubMed
    1. Boyle-Vavra, S., S. K. Berke, J. C. Lee, and R. S. Daum. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277. - PMC - PubMed
    1. Brunet, F., G. Vedal, F. Dreyfus, J. F. Vaxelaire, T. Giraud, B. Schremmer, and J. F. Monsallier. 1990. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur. J. Clin. Microbiol. Infect. Dis. 9:145-147. - PubMed

Publication types

MeSH terms